(Q33893093)

29 July 2017

0 references

Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

1 reference

Amna Sher

1

1 reference

29 July 2017

Shenhong Wu

series ordinal

2

1 reference

29 July 2017

publication date

9 May 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

50

1 reference

29 July 2017

issue

7

1 reference

29 July 2017

page(s)

997-1005

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Tumor-derived VEGF modulates hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Sunitinib-induced hemoglobin changes are related to the dosing schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Selecting and appraising studies for a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Role of c-Kit and erythropoietin receptor in erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.581689

10.3109/0284186X.2011.581689

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference